• Time: 6:30pm – 10:30pm
• The Lighthouse at Chelsea Piers, Pier 60, Chelsea Piers, New York
  23rd Street and West Side Highway, New York, New York 10011
• Website: Click to Visit…
• Tickets: $1,000 -$325  For more information, please call 212.901.8000 or email rsvp@alzdiscovery.org.

The Alzheimer’s Drug Discovery Foundation invites you to join us for the inaugural Memories Matter event. Guests can discuss the latest advances in Alzheimer’s research with ADDF scientists; take in a performance by special musical guest The Nancy Atlas Project featuring Randi Fishenfeld on violin; enjoy a seated dinner; experience desserts and decor by the talented Larry Scott Events; and bid with the best at a silent auction.

Memories Matter is generously underwritten by Stephanie and Ian Ginsberg, and Wendy Wilshin and Ronald Dickerman.

For more information, please contact rsvp@alzdiscovery.org.

• Event Contact: Jenny Iselin
  Email: jiselin@alzdiscovery.org
  Phone: 212.901.8008
  
• Press Contact:Nina Reeves
  Email: nina@ninareevescommunications.com
  Phone: 917.375.0236

The mission of the Alzheimer’s Drug Discovery Foundation is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease.

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer’s.

OUR FUNDING MODEL

We follow a venture philanthropy model, funding breakthrough research in academia and the biotech industry. Through the tremendous support of our donors, the ADDF has awarded more than $100 million to fund over 500 Alzheimer’s drug discovery programs and clinical trials in 18 countries. Twenty percent of the drugs in clinical development for Alzheimer’s disease received support from the ADDF.

OUR STRATEGY

The ADDF focuses on translating the knowledge we have gained about the causes of Alzheimer’s disease into drugs to conquer it. We support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the “valley of death” because it’s where good ideas go to die. These projects hold great promise, but also great risk. And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer’s disease that would otherwise go unexplored.

OUR FUTURE

Today, Alzheimer’s disease affects more than 44 million people and is the only top 10 cause of death that cannot be prevented, cured or slowed. But we have the power to stop this devastating disease in its tracks. By advancing the most promising research across the globe, we will conquer Alzheimer’s disease.